BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call the next day, Thursday, May 4, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the “Investor Relations” section of Anika’s website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC^®, MONOVISC^®, and CINGAL^®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST^®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, announced today that it will report financial results for the first quarter ended March 31, 2017, before the U.S. markets open on Wednesday, May 10, 2017.

The company will host a conference call to discuss these results on Wednesday, May 10, 2017, at 8:30 AM ET (3:30 PM IST). Investors within the United States interested in participating are invited to call 888-298-3457. Participants in Israel can use the toll-free dial-in number 1 80 924 5906. All other international participants can use the dial-in number 719-457-2689. For all callers, refer to Conference ID 8737181.

A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 1-866-375-1919 and reference the Replay Access Code: 8737181. All international callers can dial +1 719-457-0820, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.com and select ‘Investor Relations.’

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit www.MazorRobotics.com.

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the first quarter 2017 on Thursday, April 27, 2017, prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss first quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

TOULOUSE, France–(BUSINESS WIRE)–Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated Q1 sales results as of March 31^st, 2017.

« VEXIM sales performance in Q1 is in line with our expectations. VEXIM continues to gain market share in Europe and Internationally with a market growing around 5%. Our German business is also progressing and we remain confident to reach at least €5 million of sales there and rank among the top 3 market leaders. We maintain our guidance of 30% to 35% growth of sales and aim at reaching profitability for the full year 2017 », said Vincent Gardès, CEO of VEXIM.

Continued growth in the first quarter 2017

Revenue (€ in million – IFRS, as of March, 31^st)

€4.7 million in sales, VEXIM continues to expand in all geographies

In Europe, Vexim’s business continues to grow and the SpineJack® is becoming progressively the standard of care for vertebral fractures. In France, its domestic market, Vexim continues to grow and increase its market shares. In Germany, the biggest market in Europe (worth €70 million per year), Vexim increased the size of its salesforce to meet the growing demand of the market, for its products. With the addition of Masterflow Plus, Vexim’s secondary product specifically designed for the German market and to address a large potential of patients suffering from osteoporotic compression fractures, Vexim also gained access to Clinicpartners, Agaplesion, AGKAMed and Paul Gerhard Diakonie, counting for 250+ clinics for Vexim to sell into. Vexim will furthermore initiate a clinical study in Germany where the Spinejack® will be more evidence based towards a wider range of indications to follow. In Germany, Vexim is then pursuing the objective of achieving €5.0 million of sales in 2017, and ranking among the top 3 market leaders in the country.

Italy will see Vexim grow to achieve a 20% market share position. With the approval by Sanitas in Spain, one of the largest insurance companies, Vexim expects to see a major step forward in its market expansion in 2017.

Outside of Europe, where sales in Q1 increased by 114% vs Q1 2016, Vexim continues to see growing interest in the SpineJack® technology. As previously announced, Vexim is in the process of launching Spinejack® products in Brazil, Australia and South Korea in the coming months.

Since its launch in 2011, the Spinejack® has now been implanted to more than 46 000 patients which is close to 22 000 surgeries.

Confirmation of 2017 guidance

First quarter 2017 revenues are in line with Vexim’s expectations. The group confirms his guidance for full year 2017 :

• Sales growth of +30% to +35% (organic)
• Positive operating and net income, throughout the full year
• Sales of €5M Sales in Germany and rank among top 3 market leaders

Financial reporting schedule:
2^nd quarter sales: July 11^th, 2017¹

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital², and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 66 members on its staff. VEXIM has been listed on NYSE Alternext Paris since May 3^rd 2012. For further information, please visit www.vexim.com

SpineJack®³, an innovative implant for treating Vertebral Compression Fractures
The SpineJack® is designed to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally invasive surgery, guided by X-ray, in approximately 30 minutes, which is intended to enable the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

¹ Indicative date, subject to changes.
² Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
³ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Nom : VEXIM

Code ISIN : FR0011072602

Code mnémonique : ALVXM